Skip to main content
OpenTrials
Completed

NCT Number: NCT01278693

Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients

The purpose of this study is to determine Effect of oral L-carnitine supplement on lipid profile, anemia, and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Complication of Hemodialysis Dyslipidemias Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Lipid Metabolism Disorders Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Noor university hospital

Isfahan, Iran

About this study

In patients under maintenance hemodialysis several factors reduce the body stored carnitine which in turn affected dyslipidemia, anemia, and general health in these patients. The investigators evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life in hemodialysis patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and at least three times a week and each session almost for four hours having serum triglyceride or total cholesterol concentration >200 mg/dl or serum HDL concentration >40 mg/dl in the beginning of the study.

Exclusion criteria

taking carnitine supplement or the drug that interact with carnation lowering the seizure threshold in the last month being affected by liver function abnormalities, hypothyroidism, chronic infectious diseases (such as hepatitis), inflammatory diseases, CNS mass having the history of seizure.

Treatment and study plan

L-carnitine

Drug

500 mg,twice daily, 16 weeks

Placebo

Drug

500 mg,twice daily, 16 weeks.

Primary outcomes

  1. lipid profile

    Time frame: at sixteen weeks after admission

Secondary outcomes

  1. anemia

    Time frame: at sixteen weeks after admission

  2. quality of life

    Time frame: at sixteen weeks after admission

Sponsors and collaborators

Lead sponsor

Isfahan University of Medical Sciences

Other

Registry information

Official study title

Study of Treatment of Dyslipidemia for Hemodialysis

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jan 19, 2011
Registry last updated
Jan 19, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.